Skip to main content
See every side of every news story
Get Started
SubscribeLogin
Published • loading... • Updated

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Picked Up by Analysts at Citigroup

Summary by MarketBeat
Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday. They set a "buy" rating and a $325.00 price objective for the company.

2 Articles

Seeking AlphaSeeking Alpha
Lean Right

Nuvation stock, Jazz stock gain new Buys at Citi (NUVB:NYSE)

Nuvation Bio NUVB) stock and Jazz Pharmaceuticals (JAZZ) stock gain as Citi issues new Buy ratings on the firms based on their cancer treatments. Read more here.

·Ra'anana, Israel
Read Full Article
MarketBeatMarketBeat
Center

Jazz Pharmaceuticals (NASDAQ:JAZZ) Stock Picked Up by Analysts at Citigroup

Citigroup initiated coverage on shares of Jazz Pharmaceuticals in a research report on Wednesday. They set a "buy" rating and a $325.00 price objective for the company.

·Sioux Falls, United States
Read Full Article
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 50% of the sources are Center, 50% of the sources lean Right
50% Right

Factuality Info Icon

To view factuality data please Upgrade to Premium

Ownership

Info Icon

To view ownership data please Upgrade to Vantage

MarketBeat broke the news in Sioux Falls, United States on Wednesday, September 30, 2026.
Too Big Arrow Icon
Sources are mostly out of (0)
Blindspot Title And Logo
Stories disproportionately reported by the Left or the Right

Similar News Topics

Citigroup icon

Citigroup

Stock Markets icon

Stock Markets

Cancer icon

Cancer

Pharma icon

Pharma

United States icon

United States

News
Feed Dots Icon
For You
Search Icon
SearchBlindspot LogoBlindspotLocal